Inhibition of the binding of human ige to its receptor by tetracyclic compounds for the alleviation of ige-mediated immune response

Inhibition of the binding of human ige to its receptor by tetracyclic compounds for the alleviation of ige-mediated immune response

Disclosed are chemical agents with unexpected activity to inhibit the interactions between human immunoglobulin E (IgE) and its receptor (Fc epsilon RI) which interactions are known to be involved in triggering allergic responses. The agents may be used to module the allergic response in the treatme...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: YUAN LIU, JOHN CHU, YUKIO SUDO, MARIE-HELENE JOUVIN, XIUQI QIAN, JEAN-PIERRE KINET, Y.-S. EDMOND CHENG
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Disclosed are chemical agents with unexpected activity to inhibit the interactions between human immunoglobulin E (IgE) and its receptor (Fc epsilon RI) which interactions are known to be involved in triggering allergic responses. The agents may be used to module the allergic response in the treatment of various clinical conditions, including rhinitis, asthma, urticaria, atopic dermatitis, and anaphylacric shock. The agents can be formulated for oral, topical or parenteral administration.